Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr 20;4(4):CD002202.
doi: 10.1002/14651858.CD002202.pub2.

Hydroxyurea (hydroxycarbamide) for sickle cell disease

Sarah J Nevitt  1 , Ashley P Jones  1 , Jo Howard  2
Affiliations
Review

Hydroxyurea (hydroxycarbamide) for sickle cell disease

Sarah J Nevitt et al. Cochrane Database Syst Rev. .

Update in

Abstract

Background: Sickle cell disease (SCD) is one of the most common inherited diseases worldwide. It is associated with lifelong morbidity and a reduced life expectancy. Hydroxyurea (hydroxycarbamide), an oral chemotherapeutic drug, ameliorates some of the clinical problems of SCD, in particular that of pain, by raising fetal haemoglobin. This is an update of a previously published Cochrane Review.

Objectives: To assess the effects of hydroxyurea therapy in people with SCD (all genotypes), of any age, regardless of setting.

Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Register, comprising of references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. We also searched online trial registries.Date of the most recent search: 16 January 2017.

Selection criteria: Randomised and quasi-randomised controlled trials, of one month or longer, comparing hydroxyurea with placebo, standard therapy or other interventions for people with SCD.

Data collection and analysis: Authors independently assessed studies for inclusion, carried out data extraction and assessed the risk of bias.

Main results: Seventeen studies were identified in the searches; eight randomised controlled trials were included, recruiting 899 adults and children with SCD (haemoglobin SS (HbSS), haemoglobin SC (HbSC) or haemoglobin Sβºthalassaemia (HbSβºthal) genotypes). Studies lasted from six to 30 months.Four studies (577 adults and children with HbSS or HbSβºthal) compared hydroxyurea to placebo; three recruited individuals with only severe disease and one recruited individuals with all disease severities. There were statistically significant improvements in terms of pain alteration (using measures such as pain crisis frequency, duration, intensity, hospital admissions and opoid use), measures of fetal haemoglobin and neutrophil counts and fewer occurrences of acute chest syndrome and blood transfusions in the hydroxyurea groups. There were no consistent statistically significant differences in terms of quality of life and adverse events (including serious or life-threatening events). Seven deaths occurred during the studies, but the rates by treatment group were not statistically significantly different.Two studies (254 children with HbSS or HbSβºthal also with risk of primary or secondary stroke) compared hydroxyurea and phlebotomy to transfusion and chelation; there were statistically significant improvements in terms of measures of fetal haemoglobin and neutrophil counts, but more occurrences of acute chest syndrome and infections in the hydroxyurea and phlebotomy group. There were no consistent statistically significant differences in terms of pain alteration and adverse events (including serious or life-threatening events). Two deaths occurred during the studies (one in a the hydroxyurea treatment arm and one in the control arm), but the rates by treatment group were not statistically significantly different. In the primary prevention study, no strokes occurred in either treatment group but in the secondary prevention study, seven strokes occurred in the hydroxyurea and phlebotomy group (none in the transfusion and chelation group) and the study was terminated early.The quality of the evidence for the above two comparisons was judged as moderate to low as the studies contributing to these comparisons were mostly large and well designed (and at low risk of bias); however evidence was limited and imprecise for some outcomes such as quality of life, deaths during the studies and adverse events and results are applicable only to individuals with HbSS and HbSβºthal genotypes.Of the remaining two studies, one (22 children with HbSS or HbSβºthal also at risk of stoke) compared hydroxyurea to observation; there were statistically significant improvements in terms of measures of fetal haemoglobin and neutrophil counts but no statistically significant differences in terms of adverse events (including serious or life-threatening events).The final study (44 adults and children with HbSC) compared treatment regimens with and without hydroxyurea - there was statistically significant improvement in terms of measures of fetal haemoglobin, but no statistically significant differences in terms of adverse events (including serious or life-threatening events). No participants died in either of these studies and other outcomes relevant to the review were not reported.The quality of the evidence for the above two comparisons was judged to be very low due to the limited number of participants, the lack of statistical power (as both studies were terminated early with approximately only 20% of their target sample size recruited) and the lack of applicability to all age groups and genotypes.

Authors' conclusions: There is evidence to suggest that hydroxyurea is effective in decreasing the frequency of pain episodes and other acute complications in adults and children with sickle cell anaemia of HbSS or HbSβºthal genotypes and in preventing life-threatening neurological events in those with sickle cell anaemia at risk of primary stroke by maintaining transcranial doppler velocities. However, there is still insufficient evidence on the long-term benefits of hydroxyurea, particularly in preventing chronic complications of SCD, recommending a standard dose or dose escalation to maximum tolerated dose. There is also insufficient evidence about the long-term risks of hydroxyurea, including its effects on fertility and reproduction. Evidence is also limited on the effects of hydroxyurea on individuals with HbSC genotype. Future studies should be designed to address such uncertainties.

PubMed Disclaimer

Conflict of interest statement

Sarah Nevitt: none known. Ashley Jones: none known. Jo Howard: no declarations in relation to the use of hydroxyurea. In general, has undertaken consultancy for Bluebird Bio; AesRx; and Global Blood Therapeutics. Her institution has the following grants: NIHR grant for the POMS trial (prevention of morbidity in SCD); and an NIH grant for natural history in stroke in SCD (pending).

Figures

1
1
Study flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

BABY HUG 2011 {published data only}
    1. Adams RJ, Barredo J, Bonds DR, Brown C, Casella J, Daner L, et al. TCD in infants: A report from the BABY HUG trial. Blood 2005;106(11). [Abstract no: 952]
    1. Adams RJ, Luden J, Miller S, Wang W, Rees R, Li D, et al. TCD in infants: a report from the Baby Hug study. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9‐13; Cincinnati, Ohio. 2005:105.
    1. Alvarez O, Miller ST, Wang WC, Luo Z, McCarville MB, Schwartz GJ, et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi‐center placebo‐controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood & Cancer 2012;59(4):668‐74. [CENTRAL: 848700; CRS: 5500125000000525; PUBMED: 22294512] - PMC - PubMed
    1. Armstrong FD, Elkin TD, Brown RC, Glass P, Rana S, Casella JF, et al. Developmental function in toddlers with sickle cell anemia. Pediatrics 2013;131(2):e406‐14. [CENTRAL: 853612; CRS: 5500125000000530; PUBMED: 23296434] - PMC - PubMed
    1. Armstrong FD, Elkin TD, Brown RC, Glass P, Rees RC, Wang WC, et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood 2008;112(11):713.
Belgian Study 1996 {published data only}
    1. Ferster A, Vermylen C, Cornu G, Buyse M, Corazza F, Devalck C, et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood 1996;88(6):1960‐4. - PubMed
CHAMPS 2011 {published data only}
    1. Wang W, Brugnara C, Snyder C, Wynn L, Rogers Z, Kalinyak K, et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology 2011;152(6):771‐6. [CENTRAL: 801819; CRS: 5500125000000521; PUBMED: 21275961] - PubMed
    1. Wang WC, Snyder C, Brugnara C, Telen MJ, Steinberg MH, Wynn LW, et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood 2009; Vol. 22. [Abstract no: 819]
Jain 2012 {published data only}
    1. Jain D. Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. 4th Annual Sickle Cell Disease Research and Educational Symposium & Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14‐19; Hollywood, Florida. 2010. [Abstract no: 076]
    1. Jain DL, Sarathi V, Desai S, Bhatnagar M, Lodha A. Low fixed‐dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin 2012;36(4):323‐32. [CENTRAL: 879848; CRS: 5500125000000522; PUBMED: 22734586] - PubMed
MSH 1995 {published data only}
    1. Armstrong FD, Steinberg MH, Ballas SK, Ataga KI, Waclawiw MA, Kutlar A, et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood 2009, issue 22. [Abstract no: 1543]
    1. Ballas SK, Barton F, Castro O, Bellevue R, Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood 1995;86(10 Suppl 1):642a.
    1. Ballas SK, Barton F, Castro O, Koshy M, Bellevue R. Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63.
    1. Ballas SK, Barton FB, Waclawiw MA, Swerdlow P, Eckman JR, Pegelow CH, et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes 2006;4:59. - PMC - PubMed
    1. Ballas SK, Bauserman RL, McCarthy WF, Castro OL, Smith WR, Waclawiw MA. Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: Effect of sex,age, and geographical location. American Journal of Hematology 2010;85(8):613‐6. - PubMed
SCATE 2015 {published data only}
    1. Hankins JS, McCarville MB, Rankine‐Mullings A, Reid ME, Lobo CL, Moura PG, et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology 2015;90(12):1099‐105. [DOI: ] - PMC - PubMed
    1. NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387.
SWiTCH 2012 {published data only}
    1. Alvarez O, Yovetich NA, Scott JP, Owen W, Miller ST, Schultz W, et al. Pain and other non‐neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology 2013;88(11):932‐8. [CENTRAL: 963136; CRS: 5500125000000520; PUBMED: 23861242] - PMC - PubMed
    1. Aygun B, Mortier NA, Kesler K, Lockhart A, Schultz WH, Cohen AR, et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology 2015;169(2):262‐6. [CRS: 5500135000001418; PUBMED: 25612463] - PMC - PubMed
    1. Aygun B, Mortier NA, Kesler K, Schultz WH, Alvarez OA, Rogers ZR, et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. 53rd ASH Annual Meeting and Exposition; 2011 Dec 10‐13; San Diego, California. 2011. [Abstract no: 1044]
    1. Kwiatkowski JL, Cohen AR, Garro J, Alvarez O, Nagasubramanian R, Sarnaik S, et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology 2012;87(2):221‐3. [CENTRAL: 864015; CRS: 5500100000011226; PUBMED: 22120913] - PubMed
    1. NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 Date first received: 20 July 2005.
TWiTCH 2016 {published data only}
    1. Aygun B, Wruck LM, Schultz WH, Mueller BU, Brown C, Luchtman‐Jones L, et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology 2012;87(4):428‐30. - PubMed
    1. Helton KJ, Roberts D, Schultz WH, Davis BR, Kalfa TA, Pressel SL, et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood 2014;124(21):4052. [CENTRAL: 1261883; CRS: 5500135000001683]
    1. Imran H, Aygun B, Davis BR, Pressel SL, Herbert Schultz W, Jackson SM, et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood 2014;124(21):87. [CENTRAL: 1261882; CRS: 5500135000001682]
    1. Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open‐label, phase 3, non‐inferiority trial. Lancet 2016;387:661‐70. - PMC - PubMed
    1. Wood JC, Cohen A, Aygun B, Imran H, Luchtman‐Jones L, Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia‐ baseline findings from the Twitch trial. Blood 2013;122(21):2238. [CENTRAL: 1261881; CRS: 5500135000001681]

References to studies excluded from this review

Al‐Nood 2011 {published data only}
    1. Al‐Nood HA, Al‐Khawlani MM, Al‐Akwa A. Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients. Hemoglobin 2011, issue 1:13‐21. - PubMed
De Montalembert 2006 {published data only}
    1. Montalembert M, Bachir D, Hulin A, Gimeno L, Mogenet A, Bresson JL, et al. A phase 1 pharmacokinetics (PK) study of hydroxyurea (HU) 1,000 mg coated breakable tablets and 500mg capsules in pediatric and adult patients with sickle cell disease. Blood 2005;106(11):Abst 3194. [Abstract no: 3194] - PubMed
    1. Montalembert M, Bachir D, Hulin A, Gimeno L, Mogenet A, Bresson JL, et al. Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease. Haematologica 2006;91(12):1685‐8. - PubMed
George 2013 {published data only}
    1. George A, Aygun B, Mortier N, Sparreboom A, Ware R. A randomized controlled trial of a dose‐prediction equation to determine maximum tolerated dose of hydroxyurea in children with sickle cell anemia. Pediatric Blood & Cancer 2013;60 Suppl. [Abstract no: 588; CENTRAL: 1007869; CRS: 5500050000000224; EMBASE: 71047876]
NCT00004492 {published data only}
    1. NCT00004492. Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia. https://clinicaltrials.gov/show/NCT00004492.
NCT01848925 {published data only}
    1. NCT01848925. A Phase I Open‐label, Randomized, Safety and Efficacy Study of SANGUINATE™ at Two Doses Levels Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients. clinicaltrials.gov/show/NCT01848925 (date first received 23 April 2013).
NCT01960413 {published data only}
    1. NCT01960413. Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia. https://clinicaltrials.gov/show/NCT01960413.
NCT02149537 {published data only}
    1. NCT02149537. Risk Stratification for Clinical Severity of Sickle Cell Disease in Nigeria and Assessment of Efficacy and Safety During Treatment With Hydroxyurea. https://clinicaltrials.gov/show/NCT02149537.
Pushi 2000 {published data only}
    1. Pushi A. Hydroxyurea ameliorates importantly the clinical course of sickle cell disease reducing the frequency of painful crises. Hematology Journal 2000;1(Suppl. 1):34, Abstract no: 130.
Silva‐Pinto 2007 {published data only}
    1. Silva‐Pinto AC, Carrara RC, Oliveira VC, Palma PV, Campos AD, Zago MA, et al. Hydroxyurea treatment of sickle cell diseases causes megaloblastic transformation of the bone marrow that is responsible for the increase of the mean corpuscular volume. Haematologica 2007;Suppl 1:298.
Silva‐Pinto 2014 {published data only}
    1. Silva‐Pinto AC, Dias‐Carlos C, Saldanha‐Araujo F, Ferreira FI, Palma PV, Araujo AG, et al. Hydroxycarbamide modulates components involved in the regulation of adenosine levels in blood cells from sickle‐cell anemia patients. Annals of Hematology 2014;93(9):1457‐65. [CENTRAL: 1000846; CRS: 5500131000000084; JID:: 9107334; PUBMED: 24696091] - PubMed
Vichinsky 2013 {published data only}
    1. Vichinsky E, Torres M, Glass J, Minniti CP, Barrette S, Habr D, et al. A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD0: 2‐year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy. Blood 2011;118(21). [Abstract no: 1082]
    1. Vichinsky E, Torres M, Minniti CP, Barrette S, Habr D, Zhang Y, et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two‐year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology 2013;88(12):1068‐73. [CRS: 5500125000000523; PUBMED: 23946212] - PubMed
Voskaridou 2005 {published data only}
    1. Voskaridou E, Terpos E, Margeli A, Hantzi E, Meletis J, Papassotiriou I, et al. Renal dysfunction and osteodystrophy in patients with sickle cell thalassaemia under long‐term treatment with hydroxyurea. 10th Congress of the European Hematology Association; 2005 June 2‐5; Stockholm International Fairs, Sweden. 2005. [Abstract no: 0174]

References to studies awaiting assessment

Anyanwu 2016 {published data only}
    1. Anyanwu JN, Williams O, Sautter CL, Kasirye P, Hume H, Opoka RO, Latham T, Ndugwa C, Ware RE, John CC. Novel Use of Hydroxyurea in an African Region With Malaria: Protocol for a Randomized Controlled Clinical Trial. JMIR research protocols 2016;5(2):e110. - PMC - PubMed
NCT02560935 {published data only}
    1. NCT02560935. Primary Prevention of Stroke in Children With SCD in Sub‐Saharan Africa II (SPRING). clinicaltrials.gov/show/NCT02560935 (first received 02 September 2015).
NCT02675790 {published data only}
    1. NCT02675790. Low Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub‐Saharan Africa (SPRINT). clinicaltrials.gov/ct2/show/NCT02675790 (first received 08 January 2016).

References to ongoing studies

NCT01389024 {published data only}
    1. NCT01389024. Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease (HUPrevent). clinicaltrials.gov/ct2/show/NCT01389024 (first received 30 June 2011).

Additional references

Aumont 2015
    1. Aumont C, Driss F, Lazure T, Picard V, Creidy R, Botton S, et al. Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia. American Journal of Hematology 2015;90(7):E131‐2. - PubMed
Ballas 1996
    1. Ballas SK, Barton F, Castro O, Koshy M, Bellevue R. Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63.
Ballas 2006
    1. Ballas SK, Barton FB, Waclawiw MA, Swerdlow P, Eckman JR, Pegelow CH, et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes 2006;4:59. - PMC - PubMed
Ballas 2009
    1. Ballas SK, Guo N, DeCastro L, Bellevue R. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. JAMA 2009;101(10):1046. - PubMed
Barton 1996
    1. Barton F, Terrin M, Moore R, McMahon RP, Charache S. Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in Sickle Cell Anemia (MSH). The MSH Investigators. Controlled Clinical Trials 1996;17:67S. - PubMed
Baz 2012
    1. Baz W, Najfeld V, Yotsuya M, Talwar J, Terjanian T, Forte F. Development of myelodysplastic syndrome and acute myeloid leukemia 15 years after hydroxyurea use in a patient with sickle cell anemia. Clinical Medicine Insights. Oncology 2012;6:149‐52. - PMC - PubMed
Berk 1995
    1. Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD. Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Wasserman LR BP, Berlin NI editor(s). Polycythemia Vera and the Myeloproliferation Disorders. Philadelphia: W B Saunders, 1995:166‐94.
Bernaudin 2016
    1. Bernaudin F, Verlhac S, Arnaud C, Kamdem A, Hau I, Leveillé E, et al. Long‐term treatment follow‐up of children with sickle cell disease monitored with abnormal transcranial Doppler velocities. Blood 2016;127(15):1814‐22. [10.1182/blood‐2015‐10‐675231. Epub 2016 Feb 5.] - PubMed
Berthaut 2008
    1. Berthaut I, Guignedoux G, Kirsch‐Noir F, Larouziere V, Ravel C, Bachir D, et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica 2008;93(7):988‐93. - PubMed
Brousseau 2010
    1. Brousseau DC, A Panepinto J, Nimmer M, Hoffmann RG. The number of people with sickle‐cell disease in the United States: national and state estimates. American journal of hematology 2010 Jan 1;85(1):77‐8. - PubMed
Brozovic 1987
    1. Brozovic M, Davies SC. Management of sickle cell disease. Postgraduate Medical Journal 1987;63:605‐9. - PMC - PubMed
Chakravorty 2015
    1. Chakravorty S, Williams TN. Sickle cell disease: a neglected chronic disease of increasing global health importance. Archives of Disease in Childhood 2015;100(1):48‐53. - PMC - PubMed
Charache 1995
    1. Charache S, Terrin TL, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anaemia. New England Journal of Medicine 1995;332:1317‐22. - PubMed
Davies 1997a
    1. Davies SC, Roberts‐Harewood M. Blood transfusion in sickle cell disease. Blood Reviews 1997;11:57‐71. - PubMed
Davies 1997b
    1. Davies SC, Oni L. The management of patients with sickle cell disease. British Medical Journal 1997;315:656‐60. - PMC - PubMed
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta‐analysis involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9. - PubMed
Fruchtman 1994
    1. Fruchtman SM, Kaplan ME, Peterson P, Mack K, Berk PD, Wasserman LR. Acute leukemia (AL), hydroxyurea (HU), and polycythemia vera (PV): an analysis of risk from the Polycythemia Vera Study Group. Blood 1994;84(Suppl 1):518a.
Fuggle 1996
    1. Fuggle P, Shand PAX, Gill LJ, Davies SC. Pain, quality of life, and coping in sickle cell disease. Archives of Disease in Childhood 1996;75:199‐203. - PMC - PubMed
Gardner 2016
    1. Gardner K, Douiri A, Drasar E, Allman M, Mwirigi A, Awogbade M, et al. Survival in adults with sickle cell disease in a high income setting. Blood 2016;128(10):1436‐1438. - PubMed
Gray 1991
    1. Gray A, Anionwu EN, Davies SC, Brozovic M. Mortality in sickle cell disease: the experience of a British centre. Journal of Clinical Pathology 1991;44:459‐63. - PMC - PubMed
Green 2014
    1. Green NS, Barral S. Emerging science of hydroxyurea therapy for pediatric sickle cell disease. Pediatric research 2013;75(1‐2):196‐204. - PMC - PubMed
Grosse 2011
    1. Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa: a neglected cause of early childhood mortality. American journal of preventive medicine 2011 Dec 31;41(6):S398‐405. - PMC - PubMed
Handy 1996
    1. Handy C, Barton F, Moore R, McMahon R, Eckert S, Terrin M. Dose titration in the Multicentre Study of Hydroxyurea in Sickle Cell Anemia (MSH). Controlled Clinical Trials 1996;17(Suppl 2):92S.
Hankins 2014
    1. Hankins JS, Aygun B, Nottage K, Thornburg C, Smeltzer MP, Ware RE, et al. From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia. Medicine (Baltimore) 2014;93(28):e215. [DOI: 10.1097/MD.0000000000000215] - DOI - PMC - PubMed
Hassell 2010
    1. Hassell KL. Population estimates of sickle cell disease in the US. American journal of preventive medicine 2010 Apr 30;38(4):S512‐21. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analysis. BMJ 2003;327:557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org..
Howard 2015
    1. Howard J, Telfer P. Sickle Cell Disease in Clinical Practice. London 2015: Springer‐Verlag, 2015.
Jones 2009
    1. Jones AP, Riley RD, Williamson PR, Whitehead A. Meta‐analysis of individual patient data versus aggregate data from longitudinal clinical trials. Clinical Trials 2009;6(1):16‐27. - PubMed
Lanzkron 2013
    1. Lanzkron S, Carroll CP, Haywood Jr C. Mortality Rates and Age at Death from Sickle Cell Disease: US. 1979‐2005. Public Health Reports 2013;128:110‐116. - PMC - PubMed
Luchtman‐Jones 2016
    1. Luchtman‐Jones L, Pressel S, Hilliard L, Brown RC, Smith MG, Thompson AA, et al. Effects of hydroxyurea treatment for patients with hemoglobin SC disease. American Journal of Hematology 2016;91(2):238‐42. - PubMed
Manci 2003
    1. Manci EA, Culberson DE, Yang YM, Gardner TM, Powell R, Haynes J Jr, et al. Causes of death in sickle cell disease: an autopsy study. British Journal of Haematology 2003;123(2):359‐65. - PubMed
McGann 2011
    1. McGann PT, Howard TA, Flanagan JM, Lahti JM, Ware RE. Chromosome damage and repair in children with sickle cell anaemia and long‐term hydroxycarbamide exposure. British Journal of Haematology 2011;154(1):134‐40. - PMC - PubMed
Najean 1997
    1. Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997;90(9):3370‐7. - PubMed
National Toxicology Program 2008
    1. National Toxicology Program. NTP‐CERHR monograph on the potential human reproductive and developmental effects of hydroxyurea. NTP CERHR MON 2008; Vol. Oct, issue 21:vii‐viii, v, ix‐III1. [NIH Publication no: 08‐5993] - PubMed
NCEPOD 2008
    1. NCEPOD. ‘Sickle: A sickle crisis?’ A report of the national confidential enquiry into patient outcome and death. 2008. www.ncepod.org.uk.2008sc.html (accessed 19 September 2016).
NICE 2012
    1. National Insititute of Clinical Excellence (NICE). Sickle cell acute painful episode: management of an acute painful sickle cell episode in hospital. http://www.nice.org.uk/guidance/cg143 (accessed 06 March 2017) 2012. - PubMed
NIH 2014
    1. Evidence Based Management of Sickle Cell Disease. Expert Panel Report. National Institute of Health. 2014. www.nhlbi.nih.gov/sites/www.nhlbi.nih.gov/files/sickle‐cell‐disease‐repo... (accessed 19 September 2016).
Perrine 1978
    1. Perrine RP, Pembrey ME, John P, Perrine S, Shoup F. Natural history of sickle cell anaemia in Saudi Arabs: a study of 270 subjects. Annals of Internal Medicine 1978;88:1‐6. - PubMed
Perronne 2002
    1. Perronne V, Roberts‐Harewood M, Bachir D, Roudot‐Thoraval F, Delord JM, Thuret I, et al. Patterns of mortality in sickle cell disease in adults in France and England. Haematology Journal 2002;3(1):56‐60. - PubMed
Piel 2013
    1. Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model‐based map and population estimates. Lancet 2013;381(9861):142‐51. - PMC - PubMed
Platt 1984
    1. Platt OS, Orkin SH, Dover GJ, Beardsley GP, Miller B, Nathan DG. Hydroxyurea increases fetal hemoglobin production in sickle cell anemia. Transactions of the Association of American Physicians 1984;97:268‐74. - PubMed
Platt 1994
    1. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease ‐ life expectancy and risk factors for early death. New England Journal of Medicine 1994;330:1639‐43. - PubMed
Powars 1983
    1. Powars D, Overturf G, Turner E. Is there an increased risk of Haemophilus influenzae septicemia in sickle cell anaemia?. Pediatrics 1983;71:927‐31. - PubMed
Quinn 2010
    1. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood 2010;115:3447‐52. - PMC - PubMed
Rogers 1978
    1. Rogers DW, Clarke JM, Cupidore L, Ramlal A, Sparke BR, Serjeant GR. Early deaths in Jamaican children with sickle cell disease. British Medical Journal 1978;1:1515‐6. - PMC - PubMed
Steinberg 1999
    1. Steinberg MH. The Management of Sickle Cell Disease. New England Journal of Medicine 1999;340:1021‐30. - PubMed
Steinberg 2003
    1. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003;289(13):1645‐51. - PubMed
Steinberg 2010
    1. Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, et al. The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐up. American Journal of Hematolology 2010; Vol. 85, issue 6:403‐8. - PMC - PubMed
Sterkers 1998
    1. Sterkers Y, Preudhomme C, Lai JL, Demory JL, Caulier MT, Wattel E, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998;91(2):616‐22. - PubMed
STOP 2006
    1. Lee MT, Piomelli S, Granger S, et al. Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow‐up and final results. Blood 2006;108(3):847‐52. - PMC - PubMed
Strouse 2008
    1. Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, et al. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics 2008;122(6):1332‐43. - PubMed
Telfer 2007
    1. Telfer P, Coen P, Chakravorty S, Wilkey O, Evans J, Newell H, et al. Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London.. Haematologica 2007;92(7):905‐12. - PubMed
Terrin 1999
    1. Terrin ML, Barton FB, Bonds D, Ballas SK, Swerdlow P, Pegelow CH, et al. Effect of hydroxyurea on quality of life: 2‐year results from the multicenter study of hydroxyurea in sickle cell anemia. National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161.
Triadou 1994
    1. Triadou P, Maier‐Redelsperger M, Krishnamoorty R, Deschamps A, Casadevall N, Dunda O, et al. Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease. Nouvelle Revue Francaise d Hematologie 1994;36(5):367‐72. - PubMed
van der Plas 2011
    1. Plas EM, van den Tweel XW, Geskus RB, Heijboer H, Biemond BJ, Peters M, et al. Mortality and causes of death in children with sickle cell disease in the Netherlands, before the introduction of neonatal screening. British Journal of Haematology 2011;155(1):106‐10. - PubMed
Veith 1985
    1. Veith R, Galanello R, Papayannopoulou T, Stamatoyannopoulos G. Stimulation of F‐cell production in patients with sickle cell anaemia treated with cytarabine or hydroxyurea. New England Journal of Medicine 1985;313:1571‐5. - PubMed
Voskaridou 2010
    1. Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17‐year, single‐centre trial (LaSHS). Blood 2010;115:2354‐63. - PubMed
Ware 2006
    1. Ware RE, McMurray MA, Schultz WH, Alvarez OA, Aygun B, Cavalier ME, et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood 2006;108(11):Abst 1213.
Ware 2010
    1. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood 2010;115:5300‐11. - PMC - PubMed
Wierenga 2001
    1. Wierenga KJ, Hambleton IR, Lewis NA. Survival estimates for patients with homozygous sickle‐cell disease in Jamaica: a clinic‐based population study. Lancet 2001;357(9257):680‐3. - PubMed
Zimmerman 2004
    1. Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, et al. Sustained long‐term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004;103(6):2039‐45. - PubMed

References to other published versions of this review

Jones 2001
    1. Jones AP, Davies SC, Olujohungbe A. Hydroxyurea for sickle cell disease. Cochrane Database of Systematic Reviews 2001, Issue 2. [DOI: 10.1002/14651858.CD002202] - DOI - PubMed